Wockhardt (WOCKPHARMA) Q4 2026 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, were approved, with an unmodified audit opinion from statutory auditors.

• Board enabled a proposal to raise funds via equity or convertible/non-convertible securities, subject to shareholder approval.

Financial highlights

• Standalone revenue from operations for FY26 was ₹1,739 crore, up from ₹1,402 crore year-over-year; consolidated revenue was ₹3,373 crore, up from ₹3,012 crore.

• Standalone net profit after tax for FY26 was ₹317 crore, compared to a loss of ₹12 crore in FY25; consolidated net profit was ₹199 crore, compared to a loss of ₹57 crore.

• Standalone EPS for FY26 was ₹19.54, compared to negative ₹0.76 in FY25; consolidated EPS was ₹13.12, compared to negative ₹3.02.

• Standalone total income for Q4 FY26 was ₹571 crore, up from ₹369 crore in Q4 FY25; consolidated total income for Q4 FY26 was ₹1,010 crore, up from ₹758 crore in Q4 FY25.

Outlook and guidance

• Board approved enabling fund-raising proposals to support future growth, subject to shareholder and regulatory approvals.